Trial Profile
BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 May 2023
Price :
$35
*
At a glance
- Drugs Risankizumab (Primary) ; Ustekinumab
- Indications Plaque psoriasis; Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms UltIMMa-1
- Sponsors AbbVie; Boehringer Ingelheim
- 21 Mar 2023 Results (n=525 from studies UltIMMa-1, UltIMMa-2 and LIMMitless) assessing the long-term efficacy of RZB in patients with a history of prior biologic use presented at the American Academy of Dermatology annual Meeting 2023
- 21 Mar 2023 Results assessing the long-term improvement in difficult-to-treat areas (nail, palmoplantar, scalp) and quality of life after switch from ustekinumab (UST) to risankizumab (RZB) in patients with moderate-to-severe plaque psoriasis from UltlMMA-1 and -2 and the open-label LIMMitless extension study, presented at the American Academy of Dermatology annual Meeting 2023.
- 21 Mar 2023 Results of pooled analysis (n=1306 from four studies UltIMMa-1 and -2, IMMvent, and IMMhance) assessing racial and ethnic diversity for efficacy and safety outcomes presented at the American Academy of Dermatology annual Meeting 2023